ZXBT-1158 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZXBT-1158’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZXBT-1158 is under development for the treatment of rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), chronic lymphocytic leukemia (CLL), solid tumor, CNS lymphoma, unspecified B-cell lymphomas, mantle cell lymphoma, waldenstrom macroglobulinemia, follicular lymphoma, marginal zone lymphoma, and non-germinal center type diffuse large B-cell lymphoma. It is administered through oral route as capsule. The therapeutic candidate acts by targeting Bruton’s Tyrosine Kinase (BTK).
Guangzhou BeBetter Medicine Technology overview
Guangzhou BeBetter Medicine Technology (Guangzhou BeBetter Medicine Technology Co) that involves in developing oral biologics to treat autoimmune, inflammatory and metabolic diseases. The company is headquartered in Changsha, China.
For a complete picture of ZXBT-1158’s drug-specific PTSR and LoA scores, buy the report here.